New hope for AML patients: Three-Drug cocktail shows promise in phase 2 trial
NCT ID NCT04266795
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a drug called pevonedistat to the standard two-drug combination (venetoclax and azacitidine) helps adults recently diagnosed with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. About 164 participants received either the three-drug or two-drug regimen in 28-day cycles. The main goal was to see if the three-drug combo improved event-free survival (time without cancer worsening or death). The trial is now complete, and results will show if the extra drug offers a meaningful benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST di Monza - Azienda Ospedaliera San Gerardo
Monza, Lombardy, 20900, Italy
-
AdventHealth (Florida Hospital) - Transplant Institute
Orlando, Florida, 32804, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Azienda Ospedaliera Citta della Salute e della Scienza di Torino
Turin, Piedmont, 10126, Italy
-
Azienda Ospedaliera Universitaria Careggi
Florence, 50134, Italy
-
Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
Bologna, 40138, Italy
-
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Orbassano, Piedmont, 10043, Italy
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
CHRU Lille
Lille, 59037, France
-
CHRU Nantes
Nantes, 44093, France
-
CHRU de Poitiers La Miletrie
Poitiers, 86021, France
-
CHU de Grenoble
Grenoble, 38043, France
-
CHU de Nice
Nice, 06202, France
-
Centre Hospitalier Le Mans
Le Mans, Sarthe, 72000, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
EDOG - Institut Claudius Regaud - PPDS
Toulouse, 31059, France
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, 27100, Italy
-
Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli
Reggio Calabria, Calabria, 89133, Italy
-
HCA Midwest Health - SCRI - PPDS
Kansas City, Missouri, 64132, United States
-
Hopital Avicenne
Bobigny, 93009, France
-
Hopital Saint Antoine
Paris, 75012, France
-
Hopital Saint Louis
Paris, 75475, France
-
Hopital de L'enfant Jesus
Québec, Quebec, G1J 1Z4, Canada
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029-6574, United States
-
Institut dHematologie de Basse Normandie
Caen, 14033, France
-
Instytut Hematologii i Transfuzjologii
Warsaw, Masovian Voivodeship, 02-776, Poland
-
Intermountain LDS Hospital
Salt Lake City, Utah, 84143, United States
-
Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410, United States
-
London Health Sciences Centre
London, Ontario, N6A 5W9, Canada
-
MTZ Clinical Research Sp z o o
Warsaw, Masovian Voivodeship, 02-106, Poland
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Northwell Health Cancer Institute
Lake Success, New York, 11042, United States
-
Norton Cancer Institute - Suburban
Louisville, Kentucky, 40207, United States
-
Ospedale Santa Maria Della Misericordia Di Perugia
Perugia, Umbria, 06156, Italy
-
Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie
Lublin, 20-081, Poland
-
Stony Brook Medicine
Stony Brook, New York, 11794, United States
-
Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy
Bydgoszcz, 85-168, Poland
-
Szpital Uniwersytecki w Krakowie
Krakow, Lesser Poland Voivodeship, 31-501, Poland
-
The University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
Tom Baker Cancer Centre
Tom Baker Cancer Centre, Alberta, T2N 4N2, Canada
-
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
-
UC Irvine Medical Center
Orange, California, 92868, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of Alberta
Edmonton, Alberta, T6G 2G3, Canada
-
University of Miami Miller School of Medicine
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514-4221, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, Podlaskie Voivodeship, 15-276, Poland
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-952, Poland
-
West Virginia University Hospital
Morgantown, West Virginia, 26506, United States
-
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
Lodz, Łódź Voivodeship, 93-513, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- New drug cocktail aims to stop leukemia return after transplant
- New genetic test aims to sharpen blood cancer diagnosis
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- Blood test may personalize leukemia drug dosing
- Engineered immune cells take on tough leukemia in early trial